| 日 | 月 | 火 | 水 | 木 | 金 | 土 |
|---|---|---|---|---|---|---|
| 1 | 2 | 3 | ||||
| 4 | 5 | 6 | 7 | 8 | 9 | 10 |
| 11 | 12 | 13 | 14 | 15 | 16 | 17 |
| 18 | 19 | 20 | 21 | 22 | 23 | 24 |
| 25 | 26 | 27 | 28 | 29 | 30 | 31 |
週末なのに予定もなく自宅で犬の世話モードでしたので「国会答弁」なんぞ聞いていたのですが、3/19の参議院厚生労働委員会の小池議員の答弁は楽しかったですよ。
「ところでお伺いしたいのですが、安倍道治氏という方…厚生省在職時の直近の役職名、何をしておられましたか？」って参議院の厚生労働委員会で共産党の小池議員が質疑をしたところ、高橋局長の答弁で明らかになりましたのは…
厚生省の医薬安全局安全対策課長、医薬品副作用被害救済研究振興検査機構審議役、医薬局審査管理課長を最後にＨ１５年８月に退職したあと、外郭団体である日本公定書協会、そして中外製薬に到るまでの経歴が出てきました。ちなみに今の役職は…
中外製薬常務執行役員信頼性保証本部統轄兼信頼性保証本部長
どうでもいいけど、この安倍さん「ノーパンしゃぶしゃぶ」の愛用者だったようで…
http://www.rondan.co.jp/html/news/roran/
まぁ、日本の中央官庁にお勤めの官僚が特別ノーパンしゃぶしゃぶが愛用者ばかりじゃないとは思いたいけど、自腹でお出かけなさるとは思えませんし、誰とお出かけでしたでしょうか？
国土交通省や財務省、厚生労働省など規制当局から外郭団体に天下ってその後、企業に行って重役ってのは、どーも透明性というか信頼性がゆるがされるような気がしますなあ。
↓参議院厚生労働委員会 小池議員の質疑より
http://www.webtv.sangiin.go.jp/webtv/library/reference.php?page=1&cd=1855&tx_mode=consider&sel_kaigi_code=0&dt_singi_date_s=2007-01-25&dt_singi_date_e=2007-03-23&tx_speaker=&sel_speaker_join=AND&tx_anken=&sel_anken_join=AND&absdate=2007-03-20&sel_pageline=10&dt_calendarpoint=2007-02-23&abskaigi=no
タミフルやイレッサや薬害肝炎の並びでしたが…なかなか最初はスロースタートでしたが、なかなか楽しいですよん。残り３８分くらいの所からです。こういうつっこみを自民党とかはせーへんもんな。頭が固い共産党もそういう意味では価値がありますね・・・ない！？ ぽち→
2007年3月20日(火)「しんぶん赤旗」
固定リンク | コメント (4) | トラックバック (3)
----------------------
さて、何が出るでしょうか？ちなみに２４日から開催ですから、もう今日か明日ですね。ぽち→
http://www.fdanews.com/dailies/device/3_58/news/67657-1.html
ANALYSTS PREDICT ACC WILL INFLAME STENT WOES
The American College of Cardiology (ACC) annual meeting next week will generate more controversy about the use of drug-eluting stents (DESs), a report from RBC Capital Markets says.
"We will be treated to a rehash of all the negative data on late-stent thrombosis" in the first-generation DES systems — Boston Scientific's Taxus and Johnson & Johnson's Cypher — said the report. "We expect this to be especially harmful in the near-term outlook for [Boston Scientific], which derives about 30 percent of its total revenues from Taxus."
The analysts also wrote they expect "a lot of bad press" for the current DES platforms to come out of the conference and noted that a rebound in DES penetration is not likely to happen soon.The report added that the COURAGE trial comparing interventional procedures, such as stenting, with drug therapy alone will probably generate more uncertainties about the role of DESs. It said Abbot Laboratories' Xience stent is "likely to steal the show," with data comparing it with the Taxus.
http://www.boston.com/business/ticker/2007/03/analysts_cloud.html
A year-long sales slump in drug-coated stents made by Boston Scientific Corp. and Johnson & Johnson has not reached a bottom.
Doctors are still weighing safety risks and data to help resolve the debate remain years away.
"The first quarter is going to be pretty ugly. I expect the market to be down 10 percent to 15 percent this year," said Jeff Jonas, a portfolio manager with Gamco Medical Opportunities Fund, which owns shares of J&J.
Drug-eluting versions of the mesh tubes used to open diseased arteries quickly supplanted the older bare-metal versions when introduced over three years ago, generating almost 90 percent of all stent sales by early 2006 and creating a nearly $6 billion market.
The drug coating that prevents vessels from re-clogging was hailed a medical breakthrough. Since then, however, follow-up data on patients revealed a small but serious risk of blood clots forming long after the stent is implanted.
Patients are switching back to bare-metal stents, which cost about one-third the price of drug-eluting models.
The percentage of patients receiving drug-coated stents has fallen to the low-70s, according to Boston Scientific.
"There has been no rebound in the market," the company's chief operating officer, Paul LaViolette, said this week.
J&J said drug-coated stents were used in 75 percent to 80 percent of U.S. cases in the fourth quarter. The company declined to provide current figures.
TIMING OF RECOVERY?
Analysts said the next generation of drug-eluting stents is likely to help the market stabilize as device makers promote their benefits.
New stents in the pipeline such as Abbott Laboratories Inc.'s Xience, Medtronic Inc.'s Endeavor and J&J's CoStar may eventually help turn the tide, said J.P. Morgan analyst Mike Weinstein.
"There's a case to be made that they potentially are safer. We can't say that for certain," he said.
However, clinical data assessing the blood clot risk in the devices won't be available for two to three years.
For now, drug-eluting stent use "is declining in some labs still," said Weinstein, suggesting first-quarter sales will be lower than the level in the fourth quarter.
Leerink Swann analyst Jason Wittes said he sees the drug-coated stent market reaching a bottom eventually, but not rebounding.
"All indications are that it (the market) continues to erode," Wittes said. "It looks like we're headed toward 60 to 65 percent penetration."
One reason doctors are using more bare-metal stents is that drug-coated stents require patients to stay longer on anti-clotting drugs such as Plavix and aspirin, and some patients don't comply because of the expense, said Dr. Stephen Green, associate director of the cardiac catheterization laboratory at North Shore University Hospital in Manhasset, New York.
Still, the downturn in drug-coated stent use will reverse, he said, as patients who have received bare-metal devices return for repeat procedures six to 12 months later due to re-clogging -- the issue the drug-coated versions were developed to address in the first place.
For now, recent government actions are keeping patients wary.
U.S. Food and Drug Administration officials are urging physicians to be more cautious in using the devices "off label" in patients with harder-to-treat conditions that are not indicated for the treatment. That practice is thought to account for about 60 percent of the stents implanted.
The agency that runs the U.S. Medicare program is also looking at how it pays for drug-coated stents following an FDA panel's warning in December that the devices are riskier in some patients than in others.
Earlier this month, the U.S. House Oversight and Government Reform Committee requested safety and marketing data from the stent makers as it begins a review of the products.
Many analysts are cautious on Boston Scientific's stock even as it hovers around 4-1/2-year lows near $15. They cite the slump in demand for drug-coated stents as well as for another major product -- its implantable defibrillators that manage irregular heartbeats.
Boston Scientific stock trades at about 14 times estimated 2008 earnings, compared with about 19 times for rival Medtronic. (Reuters)
固定リンク | コメント (0) | トラックバック (1)
厚生労働省は75歳以上の高齢者を対象に、外来診療でかかる医療費を検査や投薬の数量にかかわらず、同じ病気なら定額とする「包括払い方式」を導入する方針を固めた。2008年4月から適用する。過剰診療を減らす狙いで、患者の医療費負担も減る公算が大きい。特定の主治医が外来診療から在宅ケアまで対応する公的な「かかりつけ医」制度と一体的に導入し、医療の効率化を目指す。
政府は06年の医療制度改革で、75歳以上の「後期高齢者」を対象とした新しい健康保険制度を08年度に創設することを決めた。厚労省は医師が受け取る診療報酬についても、新制度に対応した体系を今年末までにつくる予定で、外来診療への定額制導入はその柱になる。 (07:00)
-------------------------
予想されていましたが、2008年度についに高齢者向けの医療費削減の目的で、外来の医療費の定額制ですか・・・仕方ありませんが、これでかえって「検査の簡素化」で症状がさらに悪化して入院する羽目になったりしそうな気がしますが。それでも、こういう形で「キャップ」する外来医療費…そこまで高いのでしょうかね？
現行の診療報酬体系 一般診療医療費,入院－入院外・年齢階級×傷病分類別
固定リンク | コメント (0) | トラックバック (0)
